Sagimet Biosciences reports Q2 EPS (25c), consensus (33c)
PremiumThe FlySagimet Biosciences reports Q2 EPS (25c), consensus (33c)
1M ago
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Premium
Press Releases
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
1M ago
Sagimet Biosciences Expands Board with Two Key Appointments
Premium
Company Announcements
Sagimet Biosciences Expands Board with Two Key Appointments
2M ago
Sagimet Biosciences to hold a conference call
PremiumThe FlySagimet Biosciences to hold a conference call
3M ago
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 
Premium
Press Releases
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 
3M ago
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
Premium
Press Releases
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100